Addis Ababa population-based pattern of cancer therapy, Ethiopia

PLoS One. 2019 Sep 19;14(9):e0219519. doi: 10.1371/journal.pone.0219519. eCollection 2019.

Abstract

Cancer in Sub-Saharan Africa is becoming an important challenge for health services due to rising numbers of patients. In Addis Ababa with around 3.5 million inhabitants, more than 2000 cases are diagnosed annually. In this retrospective population-based cohort study we assessed completeness of and waiting time for cancer-therapy among patients registered in the Addis Ababa City Cancer Registry (AACCR), Ethiopia. Patient hospital files were retrieved to complete the data from AACCR. A total of 588 files were found (51% of those diagnosed from January to March 2012 and 2014). We analyzed completeness and waiting time of chemotherapy and radiotherapy; with completeness defined as ≥85% therapy received according to local guidelines. Analysis was done for the five most common cancer-types commonly treated with chemotherapy (breast, colorectal, non-Hodgkin`s lymphoma, lung and ovarian) and the four most common cancer-types commonly treated with radiotherapy (breast, cervical, head and neck and rectal). In our study, half of the patients (54.1%) received adequately dosed chemotherapy and 24.5% of patients received adequately dosed radiotherapy. The median waiting time was 2.1 months (Range: 0 to 20.72) for chemotherapy and 7 months (Range: 0.17 to 21.8) for radiotherapy. This study underscores the need for health system measures to improve cancer-directed therapy in Ethiopia, especially concerning radiotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Combined Modality Therapy
  • Delivery of Health Care*
  • Ethiopia / epidemiology
  • Ethnicity*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neoplasms / diagnosis
  • Neoplasms / epidemiology*
  • Neoplasms / therapy
  • Practice Patterns, Physicians'*
  • Registries
  • Retrospective Studies
  • Young Adult

Grants and funding

The research leading to these results has received funding from the German Ministry of Education and Research under grant agreement n° 01DG12006; the German Ministry for Economic and Development Cooperation (BMZ) through the ESTHER University and Hospital Partnership Initiative of German International Cooperation (GIZ); the Surveillance and Health Service Research Program, American Cancer Society and the World Health Organization country office. FJ received a doctoral fellowship by the Bayer Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.